Health-related quality-of-life outcomes from a phase II open-label trial of two different starting doses of lenvatinib in combination with everolimus for treatment of renal cell carcinoma following one prior VEGF-targeted treatment.

Cristiane Decat Bergerot,Sun Young Rha,Sumanta K. Pal,Piotr Koralewski,Daniil Stroyakovskiy,Boris Alekseev,Francis Parnis,Daniel Castellano,Jae-Lyun Lee,Kaisa Sunela,Tudor Ciuleanu,Daniel Yick Chin Heng,Hilary Glen,Wang Jinyi,Lee Bennett,Janice Pan,Karen O'Hara,Javier Puente

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 1|浏览24

暂无评分

摘要

314Background: Renal cell carcinoma (RCC) is the most common type of kidney cancer, constituting 80% to 85% of primary renal neoplasms. Preserving health-related quality of life (HRQOL) is an impor...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要